JPS59175416A - 皮膚および粘膜の角化異常治療用外用剤 - Google Patents
皮膚および粘膜の角化異常治療用外用剤Info
- Publication number
- JPS59175416A JPS59175416A JP58050700A JP5070083A JPS59175416A JP S59175416 A JPS59175416 A JP S59175416A JP 58050700 A JP58050700 A JP 58050700A JP 5070083 A JP5070083 A JP 5070083A JP S59175416 A JPS59175416 A JP S59175416A
- Authority
- JP
- Japan
- Prior art keywords
- external preparation
- interferon
- items
- preparation according
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims description 24
- 210000004877 mucosa Anatomy 0.000 title description 5
- 108010050904 Interferons Proteins 0.000 claims abstract description 36
- 102000014150 Interferons Human genes 0.000 claims abstract description 34
- 229940079322 interferon Drugs 0.000 claims abstract description 34
- 208000002741 leukoplakia Diseases 0.000 claims abstract description 16
- 201000011486 lichen planus Diseases 0.000 claims abstract description 11
- 150000005846 sugar alcohols Chemical class 0.000 claims abstract description 7
- 210000004400 mucous membrane Anatomy 0.000 claims description 14
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 6
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 239000007853 buffer solution Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 238000007493 shaping process Methods 0.000 claims 1
- 239000003860 topical agent Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 34
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract description 15
- 239000003814 drug Substances 0.000 abstract description 6
- 150000007524 organic acids Chemical class 0.000 abstract description 6
- 238000000576 coating method Methods 0.000 abstract description 4
- 239000011248 coating agent Substances 0.000 abstract description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract description 2
- 239000004386 Erythritol Substances 0.000 abstract description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 abstract description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 abstract description 2
- 235000019414 erythritol Nutrition 0.000 abstract description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 abstract description 2
- 229940009714 erythritol Drugs 0.000 abstract description 2
- 239000000600 sorbitol Substances 0.000 abstract description 2
- 238000005507 spraying Methods 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract 5
- 239000006172 buffering agent Substances 0.000 abstract 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
- 239000000499 gel Substances 0.000 description 21
- 230000003902 lesion Effects 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 206010020649 Hyperkeratosis Diseases 0.000 description 10
- 230000005856 abnormality Effects 0.000 description 9
- 230000009854 mucosal lesion Effects 0.000 description 9
- 208000001126 Keratosis Diseases 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 230000003628 erosive effect Effects 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 208000025865 Ulcer Diseases 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 210000005178 buccal mucosa Anatomy 0.000 description 4
- 239000007979 citrate buffer Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000004195 gingiva Anatomy 0.000 description 4
- 230000003780 keratinization Effects 0.000 description 4
- 210000002200 mouth mucosa Anatomy 0.000 description 4
- -1 succinic acid-sulfur hydroxide Chemical compound 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- VXXVUHAXJHEYFH-SEPHDYHBSA-N (e)-but-2-enedioic acid;sodium Chemical compound [Na].[Na].OC(=O)\C=C\C(O)=O VXXVUHAXJHEYFH-SEPHDYHBSA-N 0.000 description 2
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 206010001557 Albinism Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 206010061297 Mucosal erosion Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 206010047642 Vitiligo Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 235000015927 pasta Nutrition 0.000 description 2
- 238000010827 pathological analysis Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000000176 sodium gluconate Substances 0.000 description 2
- 229940005574 sodium gluconate Drugs 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008362 succinate buffer Substances 0.000 description 2
- KVZLHPXEUGJPAH-UHFFFAOYSA-N 2-oxidanylpropanoic acid Chemical compound CC(O)C(O)=O.CC(O)C(O)=O KVZLHPXEUGJPAH-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- IXGNPBTYYUIEBJ-UHFFFAOYSA-N C(CC(O)(C(=O)O)CC(=O)O)(=O)O.C(CC(O)(C(=O)O)CC(=O)O)(=O)O.C(CCC(=O)O)(=O)O Chemical compound C(CC(O)(C(=O)O)CC(=O)O)(=O)O.C(CC(O)(C(=O)O)CC(=O)O)(=O)O.C(CCC(=O)O)(=O)O IXGNPBTYYUIEBJ-UHFFFAOYSA-N 0.000 description 1
- 101100027969 Caenorhabditis elegans old-1 gene Proteins 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000005100 Herpetic Keratitis Diseases 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030111 Oedema mucosal Diseases 0.000 description 1
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010070835 Skin sensitisation Diseases 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- GZLGNNHEHXBCBI-UHFFFAOYSA-L [Na+].[Na+].OC(=O)C(O)C(O)C(O)=O.[O-]C(=O)C(O)C(O)C([O-])=O Chemical compound [Na+].[Na+].OC(=O)C(O)C(O)C(O)=O.[O-]C(=O)C(O)C(O)C([O-])=O GZLGNNHEHXBCBI-UHFFFAOYSA-L 0.000 description 1
- BUEFZQGUZNXUPR-UHFFFAOYSA-N [Na].[Na].[Na].C(CC(O)(C(=O)O)CC(=O)O)(=O)O.C(CC(O)(C(=O)O)CC(=O)O)(=O)O Chemical compound [Na].[Na].[Na].C(CC(O)(C(=O)O)CC(=O)O)(=O)O.C(CC(O)(C(=O)O)CC(=O)O)(=O)O BUEFZQGUZNXUPR-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- KNKDZWFHOIKECV-UHFFFAOYSA-L dipotassium 2,3,4-trihydroxy-4-oxobutanoate Chemical compound [K+].[K+].OC(=O)C(O)C(O)C(O)=O.[O-]C(=O)C(O)C(O)C([O-])=O KNKDZWFHOIKECV-UHFFFAOYSA-L 0.000 description 1
- OQOQSRMIBLJVHE-UHFFFAOYSA-L dipotassium 2-hydroxy-2-oxoacetate Chemical compound [K+].[K+].OC(=O)C(O)=O.[O-]C(=O)C([O-])=O OQOQSRMIBLJVHE-UHFFFAOYSA-L 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- SILCDLWESNHZKB-UHFFFAOYSA-L disodium 4-hydroxy-4-oxobutanoate Chemical compound [Na+].[Na+].OC(=O)CCC([O-])=O.OC(=O)CCC([O-])=O SILCDLWESNHZKB-UHFFFAOYSA-L 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 201000010884 herpes simplex virus keratitis Diseases 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 210000001847 jaw Anatomy 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004373 mandible Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 229940039748 oxalate Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000004224 potassium gluconate Substances 0.000 description 1
- 229960003189 potassium gluconate Drugs 0.000 description 1
- LCPMNMXCIHBTEX-UHFFFAOYSA-M potassium;2-hydroxypropanoate;2-hydroxypropanoic acid Chemical compound [K+].CC(O)C(O)=O.CC(O)C([O-])=O LCPMNMXCIHBTEX-UHFFFAOYSA-M 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 231100000370 skin sensitisation Toxicity 0.000 description 1
- UPMFZISCCZSDND-JJKGCWMISA-M sodium gluconate Chemical compound [Na+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O UPMFZISCCZSDND-JJKGCWMISA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940039790 sodium oxalate Drugs 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- KIJIBEBWNNLSKE-UHFFFAOYSA-M sodium;oxalic acid;hydroxide Chemical compound [OH-].[Na+].OC(=O)C(O)=O KIJIBEBWNNLSKE-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229940042129 topical gel Drugs 0.000 description 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58050700A JPS59175416A (ja) | 1983-03-25 | 1983-03-25 | 皮膚および粘膜の角化異常治療用外用剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58050700A JPS59175416A (ja) | 1983-03-25 | 1983-03-25 | 皮膚および粘膜の角化異常治療用外用剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59175416A true JPS59175416A (ja) | 1984-10-04 |
| JPH039883B2 JPH039883B2 (enrdf_load_stackoverflow) | 1991-02-12 |
Family
ID=12866173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58050700A Granted JPS59175416A (ja) | 1983-03-25 | 1983-03-25 | 皮膚および粘膜の角化異常治療用外用剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS59175416A (enrdf_load_stackoverflow) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6193130A (ja) * | 1984-10-05 | 1986-05-12 | ビオフエロン ビオヒエミシエ サブスタンツエン ゲゼルシヤフト ミツト ベシユレンクテル ハフツング ウント コムパニー | 低投与量にてヒトの各種病気を系統的に処置するためのγ‐インタフエロン含有剤 |
| JPH03500882A (ja) * | 1987-11-03 | 1991-02-28 | ジェネンテク，インコーポレイテッド | ガンマインターフェロン製剤 |
| JPH03503766A (ja) * | 1988-11-01 | 1991-08-22 | シェリング・コーポレーション | 液体窒素および組換え体ＤＮＡヒトαインターフェロンの併用による性器いぼの治療 |
| JPH0618784B2 (ja) * | 1988-07-05 | 1994-03-16 | シェリング・コーポレーション | ポドフィリンと組換えｄｎａヒト・アルファ・インターフェロンの併用による生殖器イボの治療 |
-
1983
- 1983-03-25 JP JP58050700A patent/JPS59175416A/ja active Granted
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6193130A (ja) * | 1984-10-05 | 1986-05-12 | ビオフエロン ビオヒエミシエ サブスタンツエン ゲゼルシヤフト ミツト ベシユレンクテル ハフツング ウント コムパニー | 低投与量にてヒトの各種病気を系統的に処置するためのγ‐インタフエロン含有剤 |
| JPH03500882A (ja) * | 1987-11-03 | 1991-02-28 | ジェネンテク，インコーポレイテッド | ガンマインターフェロン製剤 |
| JPH0618784B2 (ja) * | 1988-07-05 | 1994-03-16 | シェリング・コーポレーション | ポドフィリンと組換えｄｎａヒト・アルファ・インターフェロンの併用による生殖器イボの治療 |
| JPH03503766A (ja) * | 1988-11-01 | 1991-08-22 | シェリング・コーポレーション | 液体窒素および組換え体ＤＮＡヒトαインターフェロンの併用による性器いぼの治療 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH039883B2 (enrdf_load_stackoverflow) | 1991-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5977087A (en) | Topical preparation for treatment of aphthous ulcers and other lesions | |
| US4605555A (en) | Composition and method for treating keratosic disorder of skin and mucosa | |
| AU777821B2 (en) | Therapeutic compositions and methods of use thereof | |
| JP2927850B2 (ja) | 歯とその支持組織の症状の治療のための局所用製剤 | |
| EP1959988B2 (en) | Use of bovine lactoferrin for treating destructive inflammation of mucous membrane | |
| US5709873A (en) | Method of treating conditions of teeth and their supporting tissue | |
| JP2005533047A (ja) | アフタ潰瘍および単純ヘルペス病変の予防および処置のための組成物および方法 | |
| JPH11514967A (ja) | 粘膜炎症の治療用医薬の製造のためのヒアルロン酸およびｎｓａｉｄの使用 | |
| WO2022142383A1 (zh) | 一种含透明质酸的口腔用品及其制备方法 | |
| US4605556A (en) | Composition and method for treating erythematodes and mycosis | |
| US5057497A (en) | Oral method for the maintenance of healthy gingival tissues using TRF | |
| CN108324739B (zh) | 一种药物组合物及其应用、以及口腔清洁护理产品、口腔用保健品及药品 | |
| CN108339122B (zh) | 一种抗敏生物活性玻璃粉末的制备方法及应用 | |
| JPS59175416A (ja) | 皮膚および粘膜の角化異常治療用外用剤 | |
| JP3060238B2 (ja) | 口腔用組成物 | |
| US5100653A (en) | Topical compositions for treating mouth tissues | |
| JPH039884B2 (enrdf_load_stackoverflow) | ||
| WO2003105821A1 (en) | A pharmaceutical composition comprising a corticosteroid and a nonsterodial anti-inflammatory agent | |
| JPH0761933B2 (ja) | 口腔用組成物 | |
| RU2293557C2 (ru) | Средство для местного использования при лечении заболевания кожи и слизистых | |
| JPH0637379B2 (ja) | 歯周疾患治療用外用剤 | |
| RU2137461C1 (ru) | Состав для лечения заболеваний полости рта | |
| RU2830816C2 (ru) | Применение фосфолипидной эмульсии, содержащей эффективное количество дигидрокверцетина, лецитин и глицин, для лечения хронических и воспалительных заболеваний полости рта | |
| JPH09291018A (ja) | 口腔用組成物 | |
| MARSHALL | Case of pityriasis rubra pilaris with lesions of buccal mucosa |